Investigating Clonal Hematopoiesis and Neutrophil Extracellular Traps in Venous Thrombosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines the role of clonal hematopoiesis of indeterminate potential (CHIP) and neutrophil extracellular trap (NET) formation in patients under 50 years old who experience repeated venous thrombosis or thrombosis in unusual sites. It aims to determine the prevalence of CHIP and NETosis in this population, particularly in cases where traditional risk factors for thrombosis are absent. By analyzing blood samples, the study seeks to uncover potential underlying mechanisms that contribute to these thrombotic events, which could improve management strategies for affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients (male or female) less than 50 y.o with :
* Splanchnic venous territory thrombosis or
* Cerebral venous thrombosis or
* Venous thrombosis of the upper limb or
* Pulmonary embolism (1st episode if male, 2nd episode if female) unprovoked or
* 1 episode of deep vein thrombosis + 1 episode of arterial thrombosis

Exclusion Criteria:

* Presence of a major or minor transient venous thrombosis risk factor:
* Surgery within the last 3 months preceding the qualifying thrombotic episode
* Lower limb fracture with immobilization \> 3 days in the last 3 months preceding the qualifying thrombotic episode
* Presence of estro-progestational contraception
* Pregnancy
* Immobilization for acute medical reasons within the last 3 months preceding the qualifying thrombotic episode
* Air or car travel \> 6 hours
* Presence of a major or minor persistent risk factor for venous thrombosis:
* Presence of active cancer (solid cancer or hematologic malignancy)
* Chronic inflammatory digestive or joint diseases
* Ongoing treatment with heparin (low molecular weight heparin (LMWH) or unfractionated heparin (UFH))
* Presence of an abnormality on the thrombophilia test among the following abnormalities
* Protein C deficiency
* Protein S deficiency
* Anti-thrombin deficiency
* Heterozygous or homozygous factor II mutation
* Heterozygous or homozygous factor V mutation
* Presence of anti-phospholipid syndrome
* Presence of myeloproliferative neoplasia
* Presence of paroxysmal nocturnal hemoglobinuria

Where it's running

• CHU de Bordeaux, Service Hématologie Biologique
  Bordeaux, France Recruiting
• CHU de Bordeaux, Service Médecine Vasculaire
  Bordeaux, France Recruiting
• CHU de Bordeaux, Unité ambulatoire de Médecine Vasculaire
  Bordeaux, France Recruiting
• CHU de Bordeaux, Service de Neurologie
  Bordeaux, France Not yet recruiting
• CHU de Bordeaux, Service Gastro-Entérologie
  Bordeaux, France Not yet recruiting
• CHU de Lille, Service Hémostase Clinique
  Lille, France Not yet recruiting

Study contacts

• Principal investigator: Alexandre GUY — University Hospital, Bordeaux
• Study coordinator: Alexandre GUY
• Email: alexandre.guy@chu-bordeaux.fr
• Phone: 0557656478

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sivelestat added to endovascular clot retrieval for acute anterior circulation stroke

  This study tests whether giving sivelestat sodium alongside mechanical thrombectomy helps improve outcomes for adults with acute ischemic stroke due to large vessel occlusion.

  Recruiting at 2 sites Xuanwu Hospital, Beijing · Weifang, Shandong and 1 other locations · NCT07552610

• GORE VIABAHN FORTEGRA Venous Stent Post-Approval Study

  This study tests the GORE VIABAHN FORTEGRA Venous Stent in real-world patients with venous diseases to see how it performs after it is approved.

  Recruiting at 4 sites W.L.Gore & Associates · Darien, Connecticut and 3 other locations · NCT07538609

• Precision colchicine to target atherosclerosis in people with TET2-CHIP after ACS

  This study tests whether including colchicine helps post-ACS patients, guided by TET2-CHIP status, to reduce plaque growth.

  Recruiting Phase 4 Shenyang Northern Hospital · Shenyang, Liaoning · NCT07362966

• How heparins can interfere with argatroban blood tests

  This project will test whether remaining heparin in blood samples changes laboratory measurements of argatroban activity for adults treated with UFH or LMWH.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07302620

• Evaluating the risk of blood cancers in firefighters

  This study is testing if firefighters who have been exposed to harmful substances are at a higher risk for blood cancers and related conditions.

  Recruiting Wake Forest University Health Sciences · Charlotte, North Carolina · NCT06870760

• Personalized blood thinner treatment for hip and knee replacement patients

  This study is testing if personalized blood thinner treatments can better prevent blood clots and bleeding in patients getting hip or knee replacements compared to standard treatments.

  Recruiting at 12 sites Phase 4 Leiden University Medical Center · Apeldoorn, Gelderland and 12 other locations · NCT06581965

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.